Bonesupport, an emerging leader in orthobiologics for the management of bone injuries, has announced that South Africa’s largest private insurance funder, Discovery Health and the key hospital groups, Life Healthcare, Netcare, Melomed and Busamed will provide coverage for the antibiotic-eluting bone graft substitutes, Cerament G and Cerament V.
Since Bonesupport received South African market authorization for its three Cerament products in late 2020, uptake has exclusively been in the public sector. Given coverage by these organisations, who together cover 4.6 million individuals, patient access is expected to increase.
“Access to Cerament G and Cerament V is set to improve the care of patients who develop bone infections in South Africa,” said professor Nando Ferreira, limb reconstruction surgeon at Tygerberg Hospital, Cape Town, and Professor of Orthopaedics at Stellenbosch University. “They enable effective single-stage surgeries that support bone healing, prevent infection recurrence, and obviate the need for multiple surgeries.
“Our initial 18 months of experience with more than 40 patients have shown promising results.
Professor Nando Ferreira is an advisor to Bonesupport distributor in South Africa
